ArticleLeukemia2017
The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
A M Savino et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
25 papers cite it
this papercites it